dc.contributor.author | Bjørgaas, Marit Ragnhild Rokne | |
dc.contributor.author | Farstad, Hanne | |
dc.contributor.author | Christiansen, Sverre Christian | |
dc.contributor.author | Blaas, Harm-Gerd Karl | |
dc.date.accessioned | 2021-04-16T12:14:49Z | |
dc.date.available | 2021-04-16T12:14:49Z | |
dc.date.created | 2013-07-24T15:35:19Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Hormone Research in Paediatrics. 2013, 79 39-43. | en_US |
dc.identifier.issn | 1663-2818 | |
dc.identifier.uri | https://hdl.handle.net/11250/2738156 | |
dc.description.abstract | Background: Treatment with radioiodine for Graves’ disease regularly increases the level of antithyroid antibodies, and transplacental passage of stimulating thyrotropin receptor antibodies (TRAb) may cause fetal hyperthyroidism. Case presentation: A 21-year-old woman with Graves’ disease received radioiodine treatment to avoid use of antithyroid drugs in pregnancy. She became pregnant 4 months later and was euthyroid during pregnancy. In gestational week (GW) 33, she was admitted with an increased fetal heart rate of 176–180 beats/min. Fetal echocardiography indicated cardiac decompensation. The neonate had severe hyperthyroidism (free thyroxine >100 pmol/l, nv 12.0–22.0), cardiac insufficiency, insufficient weight gain, goiter and considerably accelerated skeletal age. In the mother and neonate, TRAb was >40 IU/l (nv <1.0), indicating transplacental passage of stimulating antibodies. After delivery, TRAb remained >40 IU/l in the woman, and 18 months later she underwent total thyroidectomy with subsequent decline in TRAb. In her next pregnancy, TRAb fluctuated between 38 and 17 IU/l, and repeated fetal ultrasound showed no goiter or sign of hyperthyroidism. In cord blood, TRAb was 10.9 IU/l, and the neonate had normal thyroid hormone levels. Conclusion: This case report illustrates the impact of maternal TRAb level for neonatal outcome in two successive pregnancies. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Karger Publishers | en_US |
dc.relation.uri | https://www.karger.com/Article/FullText/342644 | |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Impact of thyrotropin receptor antibody levels on fetal development in two successive pregnancies in a woman with Graves' Disease | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.pagenumber | 39-43 | en_US |
dc.source.volume | 79 | en_US |
dc.source.journal | Hormone Research in Paediatrics | en_US |
dc.identifier.doi | 10.1159/000342644 | |
dc.identifier.cristin | 1040218 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |